Madrigal Pharmaceuticals Investor Relations Material
Latest events
Q2 2025
Madrigal Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Madrigal Pharmaceuticals Inc
Access all reports
Madrigal Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of therapies for cardiovascular and metabolic diseases. The company specializes in treatments targeting nonalcoholic steatohepatitis (NASH) and other liver-related conditions. Madrigal Pharmaceuticals leverages its expertise in lipid metabolism and endocrinology to advance its pipeline of investigational therapies. The company conducts clinical research to develop novel compounds aimed at addressing unmet medical needs in liver disease and metabolic disorders. Madrigal Pharmaceuticals Inc. is headquartered in West Conshohocken, Pennsylvania, and its shares are listed on the NASDAQ.
Key slides for Madrigal Pharmaceuticals Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Madrigal Pharmaceuticals Inc
Q2 2025
Madrigal Pharmaceuticals Inc
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
MDGL
Country
🇺🇸 United States